Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou

